RITA Medical to Present at the C.E. Unterberg, Towbin Life Sciences Conference
2006年10月26日 - 9:28AM
PRニュース・ワイアー (英語)
FREMONT, Calif., Oct. 25 /PRNewswire-FirstCall/ -- RITA Medical
Systems, Inc. (NASDAQ:RITA), a publicly-traded medical device
company focused solely on cancer therapies, today announced that it
will present at the C.E. Unterberg, Towbin Life Sciences
Conference, which will take place at the Palace Hotel in New York
City. The presentation, which is scheduled for 9:00 a.m. Eastern
Time on Monday, October 30, 2006, will include a review of the
Company's business strategy and historical financial results.
Attendance at the conference is by invitation only. RITA Medical
will offer a live audio webcast of its presentation which may be
accessed at the Company's website at http://www.ritamedical.com/.
An archived replay of the presentation will also be available
approximately three hours following the live presentation and will
also be available at http://www.ritamedical.com/. About RITA
Medical Systems, Inc. RITA Medical Systems develops, manufactures
and markets innovative products for cancer patients including
radiofrequency ablation (RFA) systems and embolization products for
treating cancerous tumors as well as percutaneous vascular and
spinal access systems. The Company's oncology product lines include
implantable ports, some of which feature its proprietary Vortex(R)
technology; tunneled central venous catheters; and safety infusion
sets and peripherally inserted central catheters used primarily in
cancer treatment protocols. The radiofrequency product line also
includes the HABIB 4X resection device which coagulates a "surgical
resection plane" and is designed to facilitate a fast dissection in
order to minimize blood loss and blood transfusion during surgery.
The proprietary RITA RFA system uses radiofrequency energy to heat
tissue to a high enough temperature to ablate it or cause cell
death. In March 2000, RITA became the first RFA company to receive
specific FDA clearance for unresectable liver lesions in addition
to its previous general FDA clearance for the ablation of soft
tissue. In October 2002, RITA again became the first company to
receive specific FDA clearance, this time for the palliation of
pain associated with metastatic lesions involving bone. The Company
also distributes LC Bead embolic microspheres in the United States.
The LC Bead microspheres are injected into selected vessels to
block the blood flow feeding a tumor, causing it to shrink over
time, and are often used in combination with RFA. The RITA Medical
Systems website is at http://www.ritamedical.com/. Contact: Joseph
DeVivo, President and CEO RITA Medical Systems, Inc. 510-771-0400
EVC Group Investors: Doug Sherk Jenifer Kirtland 415-896-6820
Media: Steve DiMattia 646-277-8706 DATASOURCE: RITA Medical
Systems, Inc. CONTACT: Joseph DeVivo, President and CEO of RITA
Medical Systems, Inc., +1-510-771-0400; or Investors, Doug Sherk, ,
or Jenifer Kirtland, or , both at +1-415-896-6820, or Media, Steve
DiMattia, +1-646-277-8706, or , all of EVC Group for RITA Medical
Systems, Inc. Web site: http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 5 2024 まで 6 2024
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Rita Medical Systems (ナスダック市場): 0 recent articles
その他のRita Medical Systems (MM)ニュース記事